Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Management of CRS and ICANS after CAR-T therapy for ALL

Vipul Sheth • 13 Jul 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia CAR-T Dexamethasone

Vipul Sheth, PhD, Fred Hutchinson Cancer Research Center, Seattle, USA, comments on the management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric-antigen receptor T-cell (CAR-T) therapy for patients with acute lymphoblastic leukemia (ALL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Vipul Sheth

1:52
T-cell lineage mixed chimerism as a prognostic factor in acute leukemia & MDS after allo-HSCT
Vipul Sheth • 28 Jun 2021

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals